Sydney Howard
Nurse Practitioner · Danville, PANPI 1275208886
Payments from drug & device makers
Across 225 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$840
- Novo Nordisk$633
- AstraZeneca$606
- Lilly USA, LLC$552
- Pfizer$426
- Exact Sciences$163
- plus $897 from 18 others
What the payments were for
- Food & beverage$4,101100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 46 | $840 |
| Novo Nordisk | 40 | $633 |
| AstraZeneca | 27 | $606 |
| Lilly USA, LLC | 29 | $552 |
| Pfizer | 25 | $426 |
| Exact Sciences | 8 | $163 |
| Johnson & Johnson | 8 | $132 |
| Boehringer Ingelheim | 6 | $105 |
| Axsome Therapeutics, Inc. | 5 | $91 |
| Dexcom, Inc. | 4 | $78 |
| GSK | 4 | $63 |
| Merck | 3 | $55 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Verona Pharma, Inc. | 2 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $50 |
| Astellas Pharma US Inc | 2 | $42 |
| Scpharmaceuticals Inc. | 2 | $41 |
| Corcept Therapeutics | 2 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Abbott | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Amgen | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
How this compares
$4,117 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 44 | $51,218 |
| OzempicSemaglutide | 41 | $45,821 |
| EliquisApixaban | 51 | $45,029 |
| RybelsusSemaglutide | 32 | $41,584 |
| XareltoRivaroxaban | 41 | $38,508 |
| JardianceEmpagliflozin | 26 | $23,252 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,424 |
| MyrbetriqMirabegron | 24 | $12,000 |
| TrulicityDulaglutide | 12 | $11,379 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,667 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,681 |
| Duloxetine Hcl | 154 | $3,919 |
| Atorvastatin Calcium | 207 | $2,959 |
| Omeprazole | 151 | $2,589 |
| Valsartan | 71 | $2,559 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $633 | $87,40573 claims |
| Lilly USA, LLCMounjaro, Trulicity | $552 | $62,59856 claims |
| PfizerEliquis | $426 | $45,02951 claims |
| Johnson & JohnsonXarelto | $132 | $38,50841 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $63 | $25,09142 claims |
| Boehringer IngelheimJardiance | $105 | $23,25226 claims |
| Astellas Pharma US IncMyrbetriq | $42 | $12,00024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Danville
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.